Company Filing History:
Years Active: 2023
Title: Jun Cui: Innovator in Therapeutic Antibody Constructs
Introduction
Jun Cui is a prominent inventor based in Emeryville, CA (US). He has made significant contributions to the field of therapeutic treatments, particularly through his innovative work on antibodies targeting CD22. His research focuses on developing methods for treating diseases characterized by CD22 expression, such as B-cell lymphomas and leukemias.
Latest Patents
Jun Cui holds a patent for constructs targeting CD22 and their uses. The patent describes antibodies, including single chain variable fragment (scFv) antibodies, and constructs that comprise antibody moieties binding to the extracellular domain of CD22 or a portion thereof. The methods and compositions provided in this patent are aimed at therapeutic treatments for diseases associated with CD22 expression.
Career Highlights
Jun Cui is currently associated with Eureka Therapeutics, Inc., where he continues to advance his research in therapeutic antibody development. His work has the potential to significantly impact the treatment landscape for various hematological malignancies.
Collaborations
He collaborates with notable colleagues, including Pengbo Zhang and Yiyang Xu, who contribute to the innovative research environment at Eureka Therapeutics, Inc.
Conclusion
Jun Cui's work exemplifies the intersection of innovation and therapeutic application in the field of medicine. His contributions to antibody constructs targeting CD22 are paving the way for new treatment options for patients with B-cell lymphomas and leukemias.